SeaBeLife Biotech raises € 1 million to carry onits drug developments targeting regulated cell death


SeaBeLife Biotech raises € 1 million to carry onits drug developments targeting regulated cell death.

Roscoff, May 17th, 2021. SeaBeLife, a pharmaceutical company focused on identifying a new class of drug candidates able to deprogram regulated cell death, announces its second seed money fundraising with several Business Angels networks.

The company’s disruptive technology is based on inhibiting simultaneously two kinds of necrotic cell deaths. The therapeutic potential is major because simultaneous activation has been recently pointed as an explanation for acute pathologies, which have limited therapeutic options and are notoriously hard to treat.

In particular SeaBeLife has confirmed the promising in vivo preliminary results obtained in 2020 for two indications: acute renal failure and liver failure. Beyond acute pathologies, SeaBeLife is also looking into chronical diseases such as Parkinson’s, Alzheimer’s, or AMD (retinal degeneration). Encouraging preliminary results were generated in vitro for all these three chronic indications. The team is presently performing in vivo experiments.

Morgane Rousselot, CEO of SeaBeLife, said: “In 2020, the initial fundraising and grant from the iLab competition, enabled us to confirm our first animal proofs of concept (POC) in acute indications and also to consider development in chronic pathologies. The current fundraising from our initial investors and new Business Angels is a real success. It will allow us to confirm these results in animals and to start the preparation of the first human trials. Thus we now look forward for regulatory preclinical work for acute indications to start in early 2022, and also work on a pharmaceutical partnership for chronic indications”

Capital funds were brought in by the founders -Business Angels networks from Brittany (Breizh Angels: Finistère Angels, BSA, BA35), as well as WeLike, BAdGE and AVA Capital for a total amount of € 1 million.

Philippe Coquil, an historical investor of Finistère Angel and member of the Strategic Committee, underlined “the intent to refinance the project in order to accelerate pre-clinical development based on the good results obtained, while showing continued confidence both in the management team and the great hope to achieve first -in-class for major pathologies ”.

About SeaBeLife.The Company was founded in March 2019 in Roscoff (France) by Morgane Rousselot (CEO, PhD in Biochemistry in UPMC-CNRS-Station Biologique de Roscoff), an entrepreneur who has already participated in the founding of several start-ups.

The technical direction is assured by Claire Delehouzé (Biotechnology engineer, inventor and partner). A preclinical development engineer and a chemist were hired in 2020. The team is supported by a scientific board including key scientists and recognized experts and a strategic board composed of entrepreneurs, clinical development experts, and physicians.

SeaBeLife has built a portfolio of over 45 relevant biologically active molecules. The first molecule has demonstrated activity in in vivo “proof-of-concept” models targeting 4 different indications, out of which 2 indications are already in preclinical development.

The company is based in Roscoff (Brittany, France), operating inside the premises of the Biological Station. In vitro and in vivo experiments will be carried out by various partners in Brittany, France and internationally.

The company has received support from Technopôle Brest Iroise, SATT Ouest Valorisation, Biotech Santé Bretagne, BPI, and Région Bretagne.

Press contact :

Morgane Rousselot, Founder – CEO SeaBeLife – +33 (0)6 32 71 85 65